Striking the right balance in heart failure

Annals of Internal Medicine

Volumn 164, Issue 2, 2016, Pages 125-126

  Shah, Monica R ^a   Lauer, Michael S ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; ENALAPRIL; ENKEPHALINASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; SACUBITRIL PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE;

CREATININE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; NOTE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; AGED; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; MIDDLE AGED;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN;

EID: 84955252792     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-2587     Document Type: Note

References (10)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 293-302. [PMID: 2057034]
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: 1429-35. [PMID: 2883575]
3. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349-55. [PMID: 8614419]
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-17. [PMID: 10471456]
5. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-75. [PMID: 11759645]
6. Braunwald E. The path to an angiotensin receptor antagonistneprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015; 65: 1029-41. [PMID: 25766951] doi: 10.1016/j.jacc.2015 .01.033
7. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993-1004. [PMID: 25176015] doi: 10.1056 /NEJMoa1409077
8. Moe GW, Ezekowitz JA, O'Meara E, Lepage S, Howlett JG, Fremes S, et al; Canadian Cardiovascular Society. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015; 31: 3-16. [PMID: 25532421] doi: 10.1016/j.cjca.2014.10.022
9. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014; 168: 721-30. [PMID: 25440801] doi: 10.1016/j.ahj.2014 .07.008
10. Vodovar N, Séronde MF, Laribi S, Gayat E, Lassus J, Januzzi JL Jr, et al; GREAT Network. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail. 2015; 3: 629-36. [PMID: 26251090] doi: 10 .1016/j.jchf.2015.03.011